{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T16:16:52Z","timestamp":1773937012314,"version":"3.50.1"},"reference-count":35,"publisher":"Oncology Nursing Society (ONS)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJON"],"published-print":{"date-parts":[[2016,12,1]]},"DOI":"10.1188\/16.cjon.e139-e146","type":"journal-article","created":{"date-parts":[[2016,11,18]],"date-time":"2016-11-18T07:51:10Z","timestamp":1479455470000},"page":"E139-E146","source":"Crossref","is-referenced-by-count":7,"title":["Neuroendocrine Tumors and Lanreotide Depot: Clinical Considerations and Nurse and Patient Preferences"],"prefix":"10.1188","volume":"20","author":[{"given":"Pamela","family":"Ryan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandria","family":"Phan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daphne","family":"Adelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiko","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2016,12,1]]},"reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Adelman, D.T., Burgess, A., & Davies, P.R. (2012). Evaluation of long-acting somatostatin analog injection devices by nurses: A quantitative study. Medical Devices, 5, 103\u2013109. doi:10.2147\/MDER.S37831","DOI":"10.2147\/MDER.S37831"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Alexopoulou, O., Abrams, P., Verhelst, J., Poppe, K., Velkeniers, B., Abs, R., & Maiter, D. (2004). Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. European Journal of Endocrinology, 151, 317\u2013324.","DOI":"10.1530\/eje.0.1510317"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Antonijoan, R.M., Barbanoj, M.J., Cordero, J.A., Peraire, C., Obach, R., Valles, J., . . . Montes, M. (2004). Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers. Journal of Pharmacy and Pharmacology, 56, 471\u2013476. doi:10.1211\/0022357023123","DOI":"10.1211\/0022357023123"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Boyd, A.E., DeFord, L.L., Mares, J.E., Leary, C.C., Garris, J.L., Dagohoy, C.G., . . . Yao, J.C. (2013). Improving the success rate of gluteal intramuscular injections. Pancreas, 42, 878\u2013882. doi:10.1097\/MPA.0b013e318279d552","DOI":"10.1097\/MPA.0b013e318279d552"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Broder, M.S., Beenhouwer, D., Strosberg, J.R., Neary, M.P., & Cherepanov, D. (2015). Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: A systematic literature review. World Journal of Gastroenterology, 21, 1945\u20131955. doi:10.3748\/wjg.v21.i6.1945","DOI":"10.3748\/wjg.v21.i6.1945"},{"key":"6","unstructured":"Burbridge, B.E. (2007). Computed tomographic measurement of gluteal subcutaneous fat thickness in reference to failure of gluteal intramuscular injections. Canadian Association of Radiologists Journal, 58, 72\u201375."},{"key":"7","doi-asserted-by":"crossref","unstructured":"Capdevila, J., Sevilla, I., Alonso, V., Anton Aparicio, L., Jimenez Fonseca, P., Grande, E., . . . Garcia Alfonso, P. (2015). Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: A retrospective cross-sectional analysis. BMC Cancer, 15, 495-015\u20131512-6. doi:10.1186\/s12885-015-1512-6","DOI":"10.1186\/s12885-015-1512-6"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Caplin, M.E., Pavel, M., Cwikla, J.B., Phan, A.T., Raderer, M., Sedlackova, E., . . . Ruszniewski, P. (2014). Lanreotide in metastatic enteropancreatic neuroendocrine tumors. New England Journal of Medicine, 371, 224\u2013233. doi:10.1056\/NEJMoa1316158","DOI":"10.1056\/NEJMoa1316158"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Caplin, M.E., Ruszniewski, P.B., Pavel, M.E., Cwikla, J.B., Phan, A.T., Raderer, M., . . . Blumberg, J. (2014). Progression-free survival (PFS) with lanreotide autogel\/depot (LAN) in enteropancreatic NETs patients: The CLARINET extension study [Abstract 4107]. Journal of Clinical Oncology, 32(5s). Retrieved from http:\/\/meetinglibrary.asco.org\/content\/129870-144","DOI":"10.1200\/jco.2014.32.15_suppl.4107"},{"key":"10","unstructured":"Chan, V.O., Colville, J., Persaud, T., Buckley, O., Hamilton, S., & Torreggiani, W.C. (2006). Intramuscular injections into the buttocks: Are they truly intramuscular? European Journal of Radiology, 58, 480\u2013484. doi:S0720-048X(06)00034-9"},{"key":"11","unstructured":"Cives, M., & Strosberg, J. (2014). An update on gastroenteropancreatic neuroendocrine tumors. Oncology, 28, 749\u2013756."},{"key":"12","unstructured":"Dasari, A., Phan, A.T., Caplin, M.E., Pavel, M.E., Cwikla, J.B., Raderer, M., . . . Ruszniewski, P.B. (2015). Lanreotide depot\/autogel (LAN) in patients with neuroendocrine tumors (NETs) aged \u226465 vs. >65 years: Subgroup analyses from the CLARINET study [Abstract e15177]. Journal of Clinical Oncology, 33(Suppl.). Retrieved from http:\/\/meeting.ascopubs.org\/cgi\/content\/abstract\/33\/15_suppl\/e15177"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Falconi, M., Bartsch, D.K., Eriksson, B., Kloppel, G., Lopes, J.M., O\u2019Connor, J.M., . . . O\u2019Toole, D. (2012). ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: Well-differentiated pancreatic non-functioning tumors. Neuroendocrinology, 95, 120\u2013134. doi:10.1159\/000335587","DOI":"10.1159\/000335587"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Hallet, J., Law, C.H., Cukier, M., Saskin, R., Liu, N., & Singh, S. (2014). Exploring the rising incidence of neuroendocrine tumors: A population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer, 121, 589\u2013597. doi:10.1002\/cncr.29099","DOI":"10.1002\/cncr.29099"},{"key":"15","unstructured":"Ipsen Biopharmaceuticals. (2015). Somatuline\u00ae depot (lanreotide) [Prescribing information]. Retrieved from https:\/\/www .somatulinedepot.com"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Kulke, M.H., Anthony, L.B., Bushnell, D.L., de Herder, W.W., Goldsmith, S.J., Klimstra, D.S., . . . Jensen, R.T. (2010). NANETS treatment guidelines: Well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas, 39, 735\u2013752. doi:10.1097\/MPA.0b013e3181ebb168","DOI":"10.1097\/MPA.0b013e3181ebb168"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Kyriakakis, N., Chau, V., Lynch, J., Orme, S.M., & Murray, R.D. (2014). Lanreotide autogel in acromegaly\u2014A decade on. Expert Opinion on Pharmacotherapy, 15, 2681\u20132692. doi:10.1517\/14656566.2014.970173","DOI":"10.1517\/14656566.2014.970173"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Lewis, A.L., & Illum, L. (2010). Formulation strategies for sustained release of proteins. Therapeutic Delivery, 1, 457\u2013479.","DOI":"10.4155\/tde.10.17"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Manon, A., Wolin, E.M., Chassaing, C., Lewis, A.L., Bertocchi, L., Richard, J., & Phan, A.T. (2015). Pharmacokinetic differences between subcutaneous and intramuscular administration of lanreotide: Results from a phase I study. Journal of Clinical Oncology, 33(Suppl.), e15186.","DOI":"10.1200\/jco.2015.33.15_suppl.e15186"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Martin-Richard, M., Massuti, B., Pineda, E., Alonso, V., Marmol, M., Castellano, D., . . . Maisonobe, P. (2013). Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: A Spanish, multicentre, open-label, single arm phase II study. BMC Cancer, 13, 427. doi:10.1186\/1471-2407-13-427","DOI":"10.1186\/1471-2407-13-427"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Marty, R., Roze, S., & Kurth, H. (2012). Decision-tree model for health economic comparison of two long-acting somatostatin receptor ligand devices in France, Germany, and the UK. Medical Devices, 5, 39\u201344. doi:10.2147\/MDER.S30913","DOI":"10.2147\/MDER.S30913"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Modlin, I.M., Moss, S.F., Chung, D.C., Jensen, R.T., & Snyderwine, E. (2008). Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. Journal of the National Cancer Institute, 100, 1282\u20131289. doi:10.1093\/jnci\/djn275","DOI":"10.1093\/jnci\/djn275"},{"key":"23","unstructured":"National Comprehensive Cancer Network. (2015). NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine tumors [v.1.15]. Retrieved from https:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Oberg, K.E. (2012). The management of neuroendocrine tumours: Current and future medical therapy options. Clinical Oncology, 24, 282\u2013293. doi:10.1016\/j.clon.2011.08.006","DOI":"10.1016\/j.clon.2011.08.006"},{"key":"25","unstructured":"Palma, S., & Strohfus, P. (2013). Are IM injections IM in obese and overweight females? A study in injection technique. Applied Nursing Research, 26(4), e1\u2013e4. doi:10.1016\/j.apnr .2013.09.002"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Pavel, M., Baudin, E., Couvelard, A., Krenning, E., Oberg, K., Steinmuller, T., . . . Salazar, R. (2012). ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology, 95, 157\u2013176. doi:10.1159\/000335597","DOI":"10.1159\/000335597"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Plourde, F., Motulsky, A., Couffin-Hoarau, A.-C., Hoarau, D., Ong, H., & Leroux, J.-C. (2005). First report on the efficacy of l-alanine-based in situ-forming implants for the long-term parenteral delivery of drugs. Journal of Controlled Release, 108, 433\u2013441.","DOI":"10.1016\/j.jconrel.2005.08.016"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Poncet, G., Faucheron, J.L., & Walter, T. (2010). Recent trends in the treatment of well-differentiated endocrine carcinoma of the small bowel. World Journal of Gastroenterology, 16, 1696\u20131706.","DOI":"10.3748\/wjg.v16.i14.1696"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Ruszniewski, P.B., Caplin, M.E., Valle, J.W., Bohas, C.L., Maisonobe, P., & Atlan, P. (2014). Patient-reported satisfaction with symptom control during lanreotide autogel\/depot (LAN) treatment for carcinoid syndrome (CS) in gastroenteropancreatic neuroendocrine tumor (GEPNET)\u00a0patients: Symnet, a large multinational, cross-sectional, observational study [Abstract 273]. Journal of Clinical Oncology, 32(Suppl. 3). Retrieved from http:\/\/meetinglibrary.asco.org\/content\/123105-143","DOI":"10.1200\/jco.2014.32.3_suppl.273"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Therasse, P., Arbuck, S.G., Eisenhauer, E.A., Wanders, J., Kaplan, R.S., Rubinstein, L., . . . Gwyther, S.G. (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute, 92, 205\u2013216.","DOI":"10.1093\/jnci\/92.3.205"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Valery, C., Artzner, F., Robert, B., Gulick, T., Keller, G., Grabielle-Madelmont, C., . . . Paternostre, M. (2004). Self-association process of a peptide in solution: From beta-sheet filaments to large embedded nanotubes. Biophysical Journal, 86, 2484\u20132501. doi:S0006-3495(04)74304-0","DOI":"10.1016\/S0006-3495(04)74304-0"},{"key":"32","doi-asserted-by":"crossref","unstructured":"Vinik, A., Wolin, E.M., Audry, H., Gomez-Panzani, E.L., & ELECT Study Group. (2014). Evaluation of lanreotide depot\/autogel efficacy and safety as a carcinoid syndrome treatment (ELECT): A randomized, double-blind, placebo-controlled trial. Endocrine Practice, 22, 1068\u20131080.","DOI":"10.4158\/EP151172.OR"},{"key":"33","unstructured":"Wolin, E.M. (2012). The expanding role of somatostatin analogs in the management of neuroendocrine tumors. Gastrointestinal Cancer Research, 5, 161\u2013168."},{"key":"34","unstructured":"Wolin, E.M., Caplin, M.E., Pavel, M.E., Cwikla, J.B., Phan, A.T., & Raderer, M. (2015). Multivariate analysis of progression-free survival in the CLARINET study of lanreotide autogel\/depot vs. placebo identifies prognostic factors in neuroendocrine tumours [Abstract]. Annals of Oncology, 26(Suppl. 6), 336."},{"key":"35","doi-asserted-by":"crossref","unstructured":"Zaybak, A., Gunes, U.Y., Tamsel, S., Khorshid, L., & Eser, I. (2007). Does obesity prevent the needle from reaching muscle in intramuscular injections? Journal of Advanced Nursing, 58, 552\u2013556.","DOI":"10.1111\/j.1365-2648.2007.04264.x"}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/cjon.ons.org\/cjon\/20\/6\/neuroendocrine-tumors-and-lanreotide-depot-clinical-considerations-and-nurse-and-patient","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:52:20Z","timestamp":1763754740000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/cjon\/20\/6\/neuroendocrine-tumors-and-lanreotide-depot-clinical-considerations"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,1]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12,1]]}},"URL":"https:\/\/doi.org\/10.1188\/16.cjon.e139-e146","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"value":"1092-1095","type":"print"},{"value":"1538-067X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,1]]}}}